Literature DB >> 21444054

Pulmonary valve replacement in adults with repaired tetralogy of Fallot.

Luke J Burchill1, Rachel M Wald, Louise Harris, Jack M Colman, Candice K Silversides.   

Abstract

There is a growing population of young adults with tetralogy of Fallot. Although surgical approaches have evolved, many adults with repaired tetralogy of Fallot have been left with residual pulmonary regurgitation. Pulmonary regurgitation is an important contributor to a number of late complications including exercise limitations, right heart failure, arrhythmia, and sudden death. Because bioprosthetic valves are used in this population, clinicians must weigh the beneficial effects of pulmonary valve replacement against the associated risks, including subsequent re-operation. In this review, we will appraise the evidence supporting pulmonary valve replacement in the adult with repaired tetralogy of Fallot, as well as the optimal timing and mode of intervention.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21444054     DOI: 10.1053/j.pcsu.2011.01.016

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu        ISSN: 1092-9126


  9 in total

1.  Right Ventricular Mass is Associated with Exercise Capacity in Adults with Repaired Tetralogy of Fallot.

Authors:  Shamus O'Meagher; Martin Seneviratne; Michael R Skilton; Phillip A Munoz; Peter J Robinson; Nathan Malitz; David J Tanous; David S Celermajer; Rajesh Puranik
Journal:  Pediatr Cardiol       Date:  2015-03-21       Impact factor: 1.655

Review 2.  The Role of Cardiopulmonary Exercise Testing for Decision Making in Patients with Repaired Tetralogy of Fallot.

Authors:  Frederic Dallaire; Rachel M Wald; Ariane Marelli
Journal:  Pediatr Cardiol       Date:  2017-06-16       Impact factor: 1.655

Review 3.  Surgical treatment for adult congenital heart disease: consideration for indications and procedures.

Authors:  Kozo Matsuo; Masashi Kabasawa; Soichi Asano; Shigeru Tateno; Yasutaka Kawasoe; Yoshitomo Okajima; Naoki Hayashida; Hirokazu Murayama
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-11-08

Review 4.  Surgical and catheter procedures in adult congenital heart disease: simple national statistics of the UK tell us something.

Authors:  Hideki Uemura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-06-05

5.  Mechanical stress is associated with right ventricular response to pulmonary valve replacement in patients with repaired tetralogy of Fallot.

Authors:  Dalin Tang; Chun Yang; Pedro J Del Nido; Heng Zuo; Rahul H Rathod; Xueying Huang; Vasu Gooty; Alexander Tang; Kristen L Billiar; Zheyang Wu; Tal Geva
Journal:  J Thorac Cardiovasc Surg       Date:  2015-10-03       Impact factor: 5.209

6.  Two melodies in concert: mitral and pulmonary valve replacement late in repaired tetralogy of Fallot.

Authors:  Zhi Fang; Jia Hu; Xianglan Zhu; Ke Lin
Journal:  J Cardiothorac Surg       Date:  2015-04-17       Impact factor: 1.637

7.  Isolated pulmonary regurgitation causes decreased right ventricular longitudinal function and compensatory increased septal pumping in a porcine model.

Authors:  S Kopic; S S Stephensen; E Heiberg; H Arheden; P Bonhoeffer; M Ersbøll; N Vejlstrup; L Søndergaard; M Carlsson
Journal:  Acta Physiol (Oxf)       Date:  2017-06-29       Impact factor: 6.311

8.  Whether Pulmonary Valve Replacement in Asymptomatic Patients With Moderate or Severe Regurgitation After Tetralogy of Fallot Repair Is Appropriate: A Case-Control Study.

Authors:  Fengpu He; Zicong Feng; Qiuming Chen; Yiping Jiao; Zhongdong Hua; Hao Zhang; Keming Yang; Kunjing Pang; Minjie Lu; Kai Ma; Sen Zhang; Lei Qi; Guanxi Wang; Shoujun Li
Journal:  J Am Heart Assoc       Date:  2019-01-08       Impact factor: 5.501

9.  Serum Bile Acids in Repaired Tetralogy of Fallot: A Marker for Liver and Heart?

Authors:  Gernot Grangl; Evelyn Zöhrer; Martin Köstenberger; Alexandra Jud; Günter Fauler; Hubert Scharnagl; Tatjana Stojakovic; Robert Marterer; Andreas Gamillscheg; Jörg Jahnel
Journal:  PLoS One       Date:  2015-12-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.